The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of baseline SUVmax in patients with advanced stage follicular lymphoma receiving frontline rituximab-based therapy.
 
Paolo Strati
No Relationships to Disclose
 
Mohamed Amin Ahmed
No Relationships to Disclose
 
Nathan Hale Fowler
Consulting or Advisory Role - Bayer; Celgene; Novartis; Roche/Genentech; TG Therapeutics; Verastem
Research Funding - Abbvie; BeiGene; Celgene; Gilead Sciences; Novartis; Roche; TG Therapeutics
 
Fredrick B. Hagemeister
No Relationships to Disclose
 
Luis Fayad
No Relationships to Disclose
 
Maria Alma Rodriguez
Research Funding - Amgen (Inst); GlaxoSmithKline (Inst); Ortho Biotech (Inst); Pfizer (Inst)
 
Felipe Samaniego
No Relationships to Disclose
 
Michael Wang
Stock and Other Ownership Interests - More Health
Honoraria - Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries; Peerview
Consulting or Advisory Role - AstraZeneca; AxImmune; Bioinvent; Celgene; iOMEDICO; Janssen Research & Development; Juno Therapeutics; More Health; Pharmacyclics/Janssen; Pulse Biosciences
Research Funding - Acerta Pharma; Amgen; AstraZeneca; BeiGene; Bioinvent; Janssen Research & Development; Juno Therapeutics; Karus Therapeutics; Kite, a Gilead company; Novartis; Oncternal Therapeutics; Pharmacyclics
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Jason Westin
Consulting or Advisory Role - Celgene; Genentech/Abbvie; Kite, a Gilead company; Kite/Gilead; Novartis; ProNAi; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Celgene; Genentech; Janssen; Karyopharm Therapeutics; Kite/Gilead; Novartis; ProNAi
 
Jorge Enrique Romaguera
No Relationships to Disclose
 
Mansoor Noorani
No Relationships to Disclose
 
Karishma Phansalkar
No Relationships to Disclose
 
Chan Cheah
No Relationships to Disclose
 
Lei Feng
No Relationships to Disclose
 
Richard Eric Davis
Research Funding - Karus Therapeutics (Inst)
 
Loretta J. Nastoupil
Honoraria - Bayer; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Spectrum Pharmaceuticals
Research Funding - Celgene; Genentech/Roche; Janssen Biotech; Karus Therapeutics; LAM Therapeutics; TG Therapeutics
 
Sattva Swarup Neelapu
Honoraria - Bio Ascend; Dava Oncology; Medscape; Physicans' Education Resource
Consulting or Advisory Role - Celgene; Cell Medica; Gilead Sciences; Incyte; Kite, a Gilead company; Merck Sharp & Dohme; Novartis; Pfizer; Precision Biosciences; Unum Therapeutics
Research Funding - Acerta Pharma; Bristol-Myers Squibb; Celgene; Cellectis; Gilead Sciences; Karus Therapeutics; Kite, a Gilead company; Merck Sharp & Dohme; Pharmacyclics; poseida therapeutics; Unum Therapeutics
Travel, Accommodations, Expenses - Celgene; Chugai Pharma; Dava Oncology; Kite/Gilead; Medscape; Merck; Novartis; Pfizer; Physicans' Education Resource; Precision Biosciences; Unum Therapeutics